We will be participating at the upcoming Biotechnology Innovation Organization conference taking place in San Diego, California, June 13-16.
Members of our team will be speaking at two incredibly exciting sessions:
Tackling Post-Covid Cognitive Impairment
Wednesday, June 15th, 4:15pm – 5:15pm PDT
https://www.bio.org/events/bio-international-convention/sessions/916081
Speaker: Dr Kiri Granger, Monument Tx, CSO
Widespread evidence shows that cognitive problems are the second most commonly reported symptom (after fatigue) in the >20% of individuals globally suffering from post-COVID syndrome. 86% of people reporting memory problems said that this impacts their ability to work.
Several mechanisms have linked COVID-19 infection with cognitive impairment, but a growing body of research has demonstrated similarities in the pathology of post-COVID cognitive changes such as neuroinflammation and other brain conditions, including Alzheimer’s disease, ‘chemo brain’ and other post-viral syndromes following infections such as influenza, HIV or Ebola.
There is now an urgent need to develop both diagnostic and treatment options for post-COVID cognitive impairment. In the UK, the NHS alone has recently invested £100 million to support long-COVID services and to establish pediatric hubs to co-ordinate care for young people.
Psychedelics: What Will It Take To Get Them to Market?
Thursday, June 16th, 9:00am-10:00am PDT
https://www.bio.org/events/bio-international-convention/sessions/882166
Panellist: Paula Moran, Monument Tx, Advisory Board
The psychedelics industry has evolved from a stigmatized counterculture phenomenon to a scientifically robust industry. There is increasing acceptance of psychedelic drugs as a promising avenue for the development of new treatments of mental health disorders. Interest is being driven by their great clinical potential to treat conditions with high unmet medical needs including depression, substance-use disorders, and pain. The urgent need for new treatments in these areas has been exacerbated by the COVID-19 pandemic.
Clinical development programs are now underway following a standard regulatory route. Support from the FDA for the development of synthetic psychedelics as approved treatment options has added to the huge investor interest over the past 18 months, with VCs at the center of the investor boom. Forecasts suggest that investment in the psychedelics sector could reach $6.85 billion by 2027.
Register for the sessions via the links above or contact us directly to schedule a meeting!
